Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus.

Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, Conery A, Ausubel FM, Mylonakis E.

PLoS One. 2014 Feb 19;9(2):e89189. doi: 10.1371/journal.pone.0089189. eCollection 2014.

2.

Discovery of potential anti-infectives against Staphylococcus aureus using a Caenorhabditis elegans infection model.

Kong C, Yehye WA, Abd Rahman N, Tan MW, Nathan S.

BMC Complement Altern Med. 2014 Jan 6;14:4. doi: 10.1186/1472-6882-14-4.

3.

Identification of an Antimicrobial Agent Effective against Methicillin-Resistant Staphylococcus aureus Persisters Using a Fluorescence-Based Screening Strategy.

Kim W, Conery AL, Rajamuthiah R, Fuchs BB, Ausubel FM, Mylonakis E.

PLoS One. 2015 Jun 3;10(6):e0127640. doi: 10.1371/journal.pone.0127640. eCollection 2015.

4.
5.

Identification of novel antimicrobials using a live-animal infection model.

Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, Ausubel FM.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10414-9. Epub 2006 Jun 26.

6.

Establishment of a novel whole animal HTS technology platform for melioidosis drug discovery.

Lakshmanan U, Yap A, Fulwood J, Yichun L, Hoon SS, Lim J, Ting A, Sem XH, Kreisberg JF, Tan P, Tan G, Flotow H.

Comb Chem High Throughput Screen. 2014;17(9):790-803.

PMID:
25329838
7.

Community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus virulence toward Caenorhabditis elegans compared.

Day SR, Moore CM, Kundzins JR, Sifri CD.

Virulence. 2012 Nov 15;3(7):576-82. doi: 10.4161/viru.22120. Epub 2012 Oct 17.

8.

Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model.

Jayamani E, Rajamuthiah R, Larkins-Ford J, Fuchs BB, Conery AL, Vilcinskas A, Ausubel FM, Mylonakis E.

Antimicrob Agents Chemother. 2015 Mar;59(3):1728-37. doi: 10.1128/AAC.04198-14. Epub 2015 Jan 12.

9.

High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model.

Conery AL, Larkins-Ford J, Ausubel FM, Kirienko NV.

Curr Protoc Chem Biol. 2014 Mar 14;6(1):25-37. doi: 10.1002/9780470559277.ch130160.

10.

An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.

Kim W, Hendricks GL, Lee K, Mylonakis E.

Expert Opin Drug Discov. 2017 Jun;12(6):625-633. doi: 10.1080/17460441.2017.1319358. Epub 2017 Apr 21. Review.

PMID:
28402221
11.

Caenorhabditis elegans as a host model for community-associated methicillin-resistant Staphylococcus aureus.

Wu K, Conly J, McClure JA, Elsayed S, Louie T, Zhang K.

Clin Microbiol Infect. 2010 Mar;16(3):245-54. doi: 10.1111/j.1469-0691.2009.02765.x. Epub 2009 May 18.

12.

An efficient and novel screening model for assessing the bioactivity of extracts against multidrug-resistant Pseudomonas aeruginosa using Caenorhabditis elegans.

Zhou YM, Shao L, Li JA, Han LZ, Cai WJ, Zhu CB, Chen DJ.

Biosci Biotechnol Biochem. 2011;75(9):1746-51. Epub 2011 Sep 7.

13.

High-throughput screen for novel antimicrobials using a whole animal infection model.

Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, Casadei G, Lewis K, Carpenter AE, Ausubel FM.

ACS Chem Biol. 2009 Jul 17;4(7):527-33. doi: 10.1021/cb900084v.

14.

A correlative analysis of epidemiologic and molecular characteristics of methicillin-resistant Staphylococcus aureus clones from diverse geographic locations with virulence measured by a Caenorhabditis elegans host model.

Wu K, Zhang K, McClure J, Zhang J, Schrenzel J, Francois P, Harbarth S, Conly J.

Eur J Clin Microbiol Infect Dis. 2013 Jan;32(1):33-42. doi: 10.1007/s10096-012-1711-x. Epub 2012 Aug 18.

15.

An integrated microfluidic platform for evaluating in vivo antimicrobial activity of natural compounds using a whole-animal infection model.

Yang J, Chen Z, Ching P, Shi Q, Li X.

Lab Chip. 2013 Sep 7;13(17):3373-82. doi: 10.1039/c3lc50264c. Epub 2013 Jul 3.

PMID:
23824379
16.

Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.

Rajamuthiah R, Jayamani E, Majed H, Conery AL, Kim W, Kwon B, Fuchs BB, Kelso MJ, Ausubel FM, Mylonakis E.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5203-7. doi: 10.1016/j.bmcl.2015.09.066. Epub 2015 Sep 30.

17.

Combination therapy with thioridazine and dicloxacillin combats meticillin-resistant Staphylococcus aureus infection in Caenorhabditis elegans.

Poulsen MØ, Schøler L, Nielsen A, Skov MN, Kolmos HJ, Kallipolitis BH, Olsen A, Klitgaard JK.

J Med Microbiol. 2014 Sep;63(Pt 9):1174-80. doi: 10.1099/jmm.0.071837-0. Epub 2014 Jun 9.

PMID:
24913562
18.

A Defensin from the Model Beetle Tribolium castaneum Acts Synergistically with Telavancin and Daptomycin against Multidrug Resistant Staphylococcus aureus.

Rajamuthiah R, Jayamani E, Conery AL, Fuchs BB, Kim W, Johnston T, Vilcinskas A, Ausubel FM, Mylonakis E.

PLoS One. 2015 Jun 10;10(6):e0128576. doi: 10.1371/journal.pone.0128576. eCollection 2015.

19.

High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase.

Cheng TJ, Wu YT, Yang ST, Lo KH, Chen SK, Chen YH, Huang WI, Yuan CH, Guo CW, Huang LY, Chen KT, Shih HW, Cheng YS, Cheng WC, Wong CH.

Bioorg Med Chem. 2010 Dec 15;18(24):8512-29. doi: 10.1016/j.bmc.2010.10.036. Epub 2010 Oct 21.

PMID:
21075637
20.

An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans.

Leung CK, Wang Y, Malany S, Deonarine A, Nguyen K, Vasile S, Choe KP.

PLoS One. 2013 Apr 29;8(4):e62166. doi: 10.1371/journal.pone.0062166. Print 2013.

Supplemental Content

Support Center